Evidence map›Paper›PMID 29018938›Full record

ReviewClinical research in cardiology : official journal of the German Cardiac Society2018

Heart failure with preserved ejection fraction: current management and future strategies : Expert opinion on the behalf of the Nucleus of the "Heart Failure Working Group" of the German Society of Cardiology (DKG).

Carsten Tschöpe, Christoph Birner, Michael Böhm, Oliver Bruder, Stefan Frantz, Andreas Luchner, Lars Maier, Stefan Störk, Behrouz Kherad, Ulrich Laufs

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Clinical research in cardiology : official journal of the German Cardiac Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05256082 (Impact of Face Masks on the Six Minute Walking Distance in Pulmonary Hypertension Patients During the COVID-19 Pandemic), which is not on this map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05256082 nacompletednot on this mapstarted 2020, after this paper: background citation

Impact of Face Masks on the Six Minute Walking Distance in Pulmonary Hypertension Patients During the COVID-19 Pandemic: A Prospective, Randomized Cross-over Study

TypeinterventionalSponsorUniversity Hospital of CologneRan2020 to 2022Enrolled122ConditionsPulmonary HypertensionArmssix-minutes-walking test
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Long-term effects of device-guided slow breathing in stable heart failure patients with reduced ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2019
    Trial
  4. Noninvasive pulse contour analysis for determination of cardiac output in patients with chronic heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2018
    Trial
  5. Article
  6. Angiotensin-Converting Enzyme Inhibitory Peptide Derived from UltrafineJournal of agricultural and food chemistry · 2025
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Observational
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Carsten TschöpeDepartment of Cardiology, Universitätsmedizin Berlin, Charite, Campus Rudolf Virchow Clinic (CVK), Augustenburger Platz 1, 13353, Berlin, Germany. Carsten.tschoepe@charite.de.
Christoph BirnerGermany Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Michael BöhmInnere Medizin III-Kardiologie, Angiologie und internistische Intensivmedizin, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Homburg, Germany.
Oliver BruderDepartment of Cardiology and Angiology, Elisabeth Hospital, Essen, Germany.
Stefan FrantzDepartment of Internal Medicine III, University Halle, Halle, Germany.
Andreas LuchnerDepartment of Internal Medicine I, Clinic St. Marien, Amberg, Germany.
Lars MaierGermany Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Stefan StörkDeutsches Zentrum für Herzinsuffizienz, Universitätsklinikum und Universität Würzburg, Würzburg, Germany.
Behrouz KheradDepartment of Cardiology, Universitätsmedizin Berlin, Charite, Campus Rudolf Virchow Clinic (CVK), Augustenburger Platz 1, 13353, Berlin, Germany.ORCID http://orcid.org/0000-0003-1733-6646
Ulrich LaufsKlinik und Poliklinik für Kardiologie im Department für Innere Medizin, Neurologie und Dermatologie, Universitätsklinikum Leipzig, Leipzig, Germany.
University Hospital Regensburg · DEBerlin-Brandenburger Centrum für Regenerative Therapien · DECharité - Universitätsmedizin Berlin · DEElisabeth-Krankenhaus Essen · DEKlinikum St. Marien Amberg · DEMartin Luther University Halle-Wittenberg · DEUniversitätsklinikum des Saarlandes · DEUniversity Hospital Leipzig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

About 50% of all patients suffering from heart failure (HF) exhibit a reduced ejection fraction (EF ≤ 40%), termed HFrEF. The others may be classified into HF with midrange EF (HFmrEF 40-50%) or preserved ejection fraction (HFpEF, EF ≥ 50%). Presentation and pathophysiology of HFpEF is heterogeneous and its management remains a challenge since evidence of therapeutic benefits on outcome is scarce. Up to now, there are no therapies improving survival in patients with HFpEF. Thus, the treatment targets symptom relief, quality of life and reduction of cardiac decompensations by controlling fluid retention and managing risk factors and comorbidities. As such, renin-angiotensin-aldosterone inhibitors, diuretics, calcium channel blockers (CBB) and beta-blockers, diet and exercise recommendations are still important in HFpEF, although these interventions are not proven to reduce mortality in large randomized controlled trials. Recently, numerous new treatment targets have been identified, which are further investigated in studies using, e.g. soluble guanylate cyclase stimulators, inorganic nitrates, the angiotensin receptor neprilysin inhibitor LCZ 696, and SGLT2 inhibitors. In addition, several devices such as the CardioMEMS, interatrial septal devices (IASD), cardiac contractility modulation (CCM), renal denervation, and baroreflex activation therapy (BAT) were investigated in different forms of HFpEF populations and some of them have the potency to offer new hopes for patients suffering from HFpEF. On the basic research field side, lot of new disease-modifying strategies are under development including anti-inflammatory drugs, mitochondrial-targeted antioxidants, new anti-fibrotic and microRNA-guided interventions are under investigation and showed already promising results. This review addresses available data of current best clinical practice and management approaches based on expert experiences and summarizes novel approaches towards HFpEF.

Indexed as

Risk Reduction BehaviorStroke VolumeVentricular Function, LeftCardiovascular AgentsComorbidityDiet, HealthyEvidence-Based MedicineExerciseHeart FailureHumansRecovery of FunctionRisk FactorsTreatment OutcomeCardiovascular AgentsHeart failureHFpEF

Identifiers

PMID29018938
OpenAlexW2763584496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.